205 related articles for article (PubMed ID: 30733293)
1. Therapeutic targeting of HER2-CB
Blasco-Benito S; Moreno E; Seijo-Vila M; Tundidor I; Andradas C; Caffarel MM; Caro-Villalobos M; Urigüen L; Diez-Alarcia R; Moreno-Bueno G; Hernández L; Manso L; Homar-Ruano P; McCormick PJ; Bibic L; Bernadó-Morales C; Arribas J; Canals M; Casadó V; Canela EI; Guzmán M; Pérez-Gómez E; Sánchez C
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3863-3872. PubMed ID: 30733293
[TBL] [Abstract][Full Text] [Related]
2. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
Pérez-Gómez E; Andradas C; Blasco-Benito S; Caffarel MM; García-Taboada E; Villa-Morales M; Moreno E; Hamann S; Martín-Villar E; Flores JM; Wenners A; Alkatout I; Klapper W; Röcken C; Bronsert P; Stickeler E; Staebler A; Bauer M; Arnold N; Soriano J; Pérez-Martínez M; Megías D; Moreno-Bueno G; Ortega-Gutiérrez S; Artola M; Vázquez-Villa H; Quintanilla M; Fernández-Piqueras J; Canela EI; McCormick PJ; Guzmán M; Sánchez C
J Natl Cancer Inst; 2015 Jun; 107(6):djv077. PubMed ID: 25855725
[TBL] [Abstract][Full Text] [Related]
3. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.
Moreno E; Andradas C; Medrano M; Caffarel MM; Pérez-Gómez E; Blasco-Benito S; Gómez-Cañas M; Pazos MR; Irving AJ; Lluís C; Canela EI; Fernández-Ruiz J; Guzmán M; McCormick PJ; Sánchez C
J Biol Chem; 2014 Aug; 289(32):21960-72. PubMed ID: 24942731
[TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
Baldassarre T; Truesdell P; Craig AW
Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
[TBL] [Abstract][Full Text] [Related]
6. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
De Cola A; Volpe S; Budani MC; Ferracin M; Lattanzio R; Turdo A; D'Agostino D; Capone E; Stassi G; Todaro M; Di Ilio C; Sala G; Piantelli M; Negrini M; Veronese A; De Laurenzi V
Cell Death Dis; 2015 Jul; 6(7):e1823. PubMed ID: 26181203
[TBL] [Abstract][Full Text] [Related]
7. Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.
Blasco-Benito S; Seijo-Vila M; Caro-Villalobos M; Tundidor I; Andradas C; García-Taboada E; Wade J; Smith S; Guzmán M; Pérez-Gómez E; Gordon M; Sánchez C
Biochem Pharmacol; 2018 Nov; 157():285-293. PubMed ID: 29940172
[TBL] [Abstract][Full Text] [Related]
8. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
9. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER2 in Advanced Breast Cancer.
Zhu X; Joy AA
Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
13. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Xu X; De Angelis C; Burke KA; Nardone A; Hu H; Qin L; Veeraraghavan J; Sethunath V; Heiser LM; Wang N; Ng CKY; Chen ES; Renwick A; Wang T; Nanda S; Shea M; Mitchell T; Rajendran M; Waters I; Zabransky DJ; Scott KL; Gutierrez C; Nagi C; Geyer FC; Chamness GC; Park BH; Shaw CA; Hilsenbeck SG; Rimawi MF; Gray JW; Weigelt B; Reis-Filho JS; Osborne CK; Schiff R
Clin Cancer Res; 2017 Sep; 23(17):5123-5134. PubMed ID: 28487443
[No Abstract] [Full Text] [Related]
14. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
15. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
16. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
17. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Yeh ES; Abt MA; Hill EG
Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
[TBL] [Abstract][Full Text] [Related]
19. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
20. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
